X. Li

Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial

Meiqi Shi, Hai‐Yan Tu, Cheng Huang et al. · Annals of Oncology · 2020 · 71 citations · Full text

Medicine, Oncology, Pharmacology +17

VP9-2021: ORIENT-31: Phase III study of sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated nonsquamous NSCLC who progressed after EGFR-TKI therapy

Shun Lü, Lin Wu, Hong Jian et al. · Annals of Oncology · 2021 · 35 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

653O Glecirasib (KRAS G12C inhibitor) in combination with JAB-3312 (SHP2 inhibitor) in patients with KRAS p.G12C mutated solid tumors

Juan Wang, Jun Zhao, Jia Zhong et al. · Annals of Oncology · 2023 · 27 citations · Full text

Medicine, Oncology, Pharmacology +9

1300P A phase Ib/II trial of AK104 (PD-1/CTLA-4 bispecific antibody) in combination with anlotinib in advanced NSCLC

Lin Wu, Bolin Chen, W. Yao et al. · Annals of Oncology · 2021 · 23 citations

Pharmacy, Oncology, Pharmacology +13

96O Camrelizumab or placebo plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-sq): A randomized, double-blind, multicenter, phase III trial

C. Zhou, Shengxiang Ren, J. Chen et al. · Journal of Thoracic Oncology · 2021 · 20 citations · Full text

Medicine, Oncology, Pharmacology +9